Company / Cash & Equivalents
ENDONOVO THERAPEUTICS, INC. Cash & Equivalents History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$85.9K
FY2021
5-year range
$13.4K / $379.2K
FY2017-FY2021
Trend
+540.4%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +540% YoY in FY2021, a notable deviation from the 7-year average annual change of +719%.
Based on SEC 10-K filings.
$85,936 in FY2021 with a 10-year CAGR of +2.1%.
Improved from $18,893 to $85,936 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -39.0%
- 5-Year CAGR
- +9.1%
- 10-Year CAGR
- +2.1%
Key checks
Key Insights
- 5-year CAGR of +9.1%, indicating consistent growth.
- In FY2021, cash & equivalents increased 540.4% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
- Lowest cash & equivalents in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | $85.9K | +540.4% |
| FY2020 | $13.4K | -29.0% |
| FY2019 | $18.9K | -95.0% |
| FY2018 | $379.2K | +582.7% |
| FY2016 | $55.5K | +33.9% |
| FY2015 | $41.5K | +4097.7% |
| FY2014 | $988 | -98.6% |
| FY2011 | $69.7K | - |
As of FY2021 · SEC 10-K · Updated Jun 29, 2026